Ohr Pharmaceutical, Inc.
| Nasdaq: OHRP
Ohr Pharmaceutical, Inc. operates as a biotechnology company, which is focused on the development of its acquired compounds. Its products include OHR/AVR 118 for the treatment of Cancer Cachexia and EVIZON, which are used for the treatment of the wet form of age related macular degeneration. The company was founded in 2008 and is headquartered in New York, NY.